GE Healthcare subsidiary expands radiation therapy partnership with Elekta

MedTech Dive, an Industry Dive publication · MedTech Dive · Industry Dive

In This Article:

Dive Brief:

  • GE Healthcare subsidiary MIM Software will expand a partnership with Elekta to develop radiation therapy software.

  •  Nearly two-thirds of cancer patients receive radiation therapy, GE Healthcare said in a statement. The time between diagnosis and treatment can take weeks, due to a lack of interoperability. 

  • The partnership will build on an existing commercial collaboration agreement between GE Healthcare and Elekta that involves selling imaging and radiation therapy equipment to hospitals.

Dive Insight:

Cleveland, Ohio-based MIM makes software to help simplify complex treatment plans in radiology. It also makes image analysis and clinician workflow tools across other specialties, including neurology and cardiology. GE Healthcare acquired MIM earlier this month for an undisclosed amount. 

Stockholm, Sweden-based Elekta makes radiation therapy machines. The company estimates it has a 42% share of the global market. 

Combined, the companies plan to innovate software solutions to improve workflows and increase throughput for clinicians, as well as offer more precise treatments and less time at the hospital for patients. 

They also hope to improve the time to treatment and enable advanced and innovative oncology treatment planning for radiation therapy. 

“Our decision to join [GE Healthcare] was driven by a ‘shared vision of maximizing impact’ and our motivation for this collaboration with Elekta is no different,” MIM CEO Andy Nelson said in a Monday statement. “For decades, we have engaged directly with clinicians to understand their needs and bridge the divide by building solutions that streamline their clinical workflows and reduce treatment delays for patients.” 

Elekta sees the partnership as a natural expansion of its portfolio, while MIM sees an opportunity to extend its reach. Both companies’ solutions are vendor-agnostic.

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.